Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results

Key Points

• Zentalis Pharmaceuticals reported an earnings per share (EPS) of ($0.37), exceeding analysts' expectations of ($0.56) by $0.19.
• The company's stock experienced a 5.1% increase following the earnings release, with current trading around $1.45.
• Analysts have mixed forecasts for Zentalis, with target prices ranging from $4.00 to $10.00, reflecting an average rating of "Moderate Buy."

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) released its earnings results on Friday. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.19, Zacks reports.

Zentalis Pharmaceuticals Stock Up 5.1%

Shares of NASDAQ:ZNTL opened at $1.45 on Friday. The business's 50 day moving average is $1.37 and its 200 day moving average is $1.57. Zentalis Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $5.44. The stock has a market cap of $104.33 million, a price-to-earnings ratio of -0.64 and a beta of 1.71.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A hedge fund recently raised its stake in Zentalis Pharmaceuticals stock. Millennium Management LLC increased its stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 220.6% during the first quarter, according to its most recent filing with the SEC. The fund owned 3,069,514 shares of the company's stock after buying an additional 2,111,951 shares during the quarter. Millennium Management LLC owned 4.27% of Zentalis Pharmaceuticals worth $4,881,000 at the end of the most recent quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ZNTL shares. Wells Fargo & Company reduced their target price on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating for the company in a research note on Thursday. HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Finally, Wedbush restated a "neutral" rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $8.20.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.